Enantioselective Synthesis of PPAR (Peroxisome Proliferator-Activated Receptors) Agonists and Antagonists

被引：1

作者：

Goya, Pilar ^{[1
]}

Perez-Fernandez, Ruth ^{[1
]}

Gonzalez-Muniz, Rosario ^{[1
]}

Elguero, Jose ^{[1
]}

机构：

[1] CSIC, Inst Quim Med, E-28006 Madrid, Spain

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2014年 / 14卷 / 10期

关键词：

PPAR; enantioselective separation; enantioselective synthesis; Evans' chiral auxiliary; asymmetric hydrogenation; chiral HPLC; chiral salts; PHENYLPROPANOIC ACID-DERIVATIVES; EFFICIENT ASYMMETRIC-SYNTHESIS; ALPHA/GAMMA DUAL AGONISTS; LIGAND-BINDING DOMAIN; BIOLOGICAL EVALUATION; ALPHA AGONIST; DESIGN; POTENCY; AGENTS;

D O I：

10.2174/1568026614666140423112822

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

This review deals with stereoselective issues in PPAR ligands some of which are in clinical use for treating certain metabolic disorders. After a short introduction of these nuclear receptor and their agonists, some cases of enantioselective separations are reported. The main part concerns stereoselective synthesis first starting with asymmetric synthesis from chiral precursors followed by what we refer to as "true" enantioselective methods. Some examples are discussed in detail for each particular heading.

引用

页码：1283 / 1293

页数：11

共 50 条

[21] Discovery of Novel Peroxisome Proliferator-Activated Receptor α (PPARα) Agonists by Virtual Screening and Biological Evaluation
Dai, Liang
Feng, Zhiqi
Zha, Rili
Cheng, Keguang
Wen, Xiaoan
Sun, Hongbin
Yuan, Haoliang
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2020, 60 (03) : 1717 - 1727
[22] In-silico identification of peroxisome proliferator-activated receptor (PPAR)α/γ agonists from Ligand Expo Components database
Feng, Xiao-Yan
Ding, Ting-Ting
Liu, Ya-Ya
Xu, Wei-Ren
Cheng, Xian-Chao
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (05) : 1853 - 1864
[23] Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures
Oyama, Takuji
Toyota, Kenji
Waku, Tsuyoshi
Hirakawa, Yuko
Nagasawa, Naoko
Kasuga, Jun-ichi
Hashimoto, Yuichi
Miyachi, Hiroyuki
Morikawa, Kosuke
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2009, 65 : 786 - 795
[24] Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence
Matheson, Justin
Le Foll, Bernard
CELLS, 2020, 9 (05)
[25] Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond
Jones, AB
MEDICINAL RESEARCH REVIEWS, 2001, 21 (06) : 540 - 552
[26] The Role of Peroxisome Proliferator-Activated Receptors in Endometrial Cancer
Psilopatis, Iason
Vrettou, Kleio
Troungos, Constantinos
Theocharis, Stamatios
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
[27] Biology and Therapeutic Applications of Peroxisome Proliferator-Activated Receptors
Menendez-Gutierrez, Maria P.
Roszer, Tamas
Ricote, Mercedes
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (06) : 548 - 584
[28] Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present)
Lamers, Christina
Schubert-Zsilavecz, Manfred
Merk, Daniel
EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (07) : 803 - 841
[29] Peroxisome proliferator-activated receptors and inflammation: take it to heart
Smeets, P. J. H.
Planavila, A.
van der Vusse, G. J.
van Bilsen, M.
ACTA PHYSIOLOGICA, 2007, 191 (03) : 171 - 188
[30] It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis
Boateng, Eistine
Bonilla-Martinez, Rocio
Ahlemeyer, Barbara
Garikapati, Vannuruswamy
Alam, Mohammad Rashedul
Trompak, Omelyan
Oruqaj, Gani
El-Merhie, Natalia
Seimetz, Michael
Ruppert, Clemens
Guenther, Andreas
Spengler, Bernhard
Karnati, Srikanth
Baumgart-Vogt, Eveline
RESPIRATORY RESEARCH, 2024, 25 (01)

← 1 2 3 4 5 →